Roland Goette, Executive Vice President and President of EMEA at Becton Dickinson & Co (NYSE:BDX), has recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Goette sold 5,121 shares of common stock over two transactions, yielding approximately $1.13 million. The sales were executed at prices ranging from $219.03 to $221.01 per share.
In addition to these sales, Goette exercised stock appreciation rights, acquiring 13,334 shares of common stock at prices between $147.68 and $167.91. These transactions were part of a pre-arranged trading plan under Rule 10b5-1, which Goette adopted on September 6, 2024. Following these transactions, Goette now directly owns 14,217 shares of Becton Dickinson's common stock. InvestingPro analysis indicates the stock is currently undervalued, with additional insights available through the comprehensive Pro Research Report, which provides detailed insider trading patterns and valuation metrics.
In other recent news, Becton Dickinson (BD) revealed strong financial results in its fourth quarter and full-year fiscal 2024 earnings call. The medical technology company reported a revenue growth of 7.4% in Q4 and a full-year organic revenue increase of 5%. Adjusted diluted earnings per share (EPS) rose by 11.4%, reaching $13.14 for the full year. Despite challenges in China and the Bioscience-Pharma sector, BD's MedTech and Diagnostics segments grew by 5.9%, with the company's medical biologic drug delivery sales surpassing $1 billion.
In terms of future developments, BD anticipates revenue between $21.9 billion and $22.1 billion for fiscal year 2025, with an adjusted diluted EPS guidance of $14.25 to $14.60. The company also announced a $1 billion share repurchase plan and increased its dividend by 9.5%. However, BD expects a mid-single-digit decline in China due to value-based procurement pressures and anticipates its Q1 performance to be below the overall guidance.
The company is optimistic about the continued growth of key products such as Alaris and expects high single-digit revenue growth for fiscal year 2025. Additionally, innovations in biologics and diagnostics, along with the integration of the Advanced Patient Monitoring business, are expected to drive growth. These are among the recent developments at BD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.